DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation, commonly referred to as DMK, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1990, the company has established itself as a leader in the development and manufacturing of innovative pharmaceutical products, particularly in the areas of dermatology and wound care. With a strong operational presence across North America and Europe, DMK Pharmaceuticals is renowned for its commitment to quality and efficacy. The company’s core offerings include advanced topical formulations and therapeutic solutions that address a variety of skin conditions, setting them apart through their unique blend of science and nature. Recognised for its dedication to research and development, DMK has achieved significant milestones, including numerous patents and awards that underscore its market position. As a trusted name in the pharmaceutical sector, DMK Pharmaceuticals continues to enhance patient care through its cutting-edge products and solutions.
DitchCarbon Score
How does DMK Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DMK Pharmaceuticals Corporation's score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DMK Pharmaceuticals Corporation's reported carbon emissions
In 2023, DMK Pharmaceuticals Corporation reported total carbon emissions of approximately 86,035,380 kg CO2e. This figure includes about 8,046,030 kg CO2e from Scope 1 emissions and approximately 76,989,350 kg CO2e from Scope 2 emissions, based on a market-based approach. The company has disclosed emissions data for both Scope 1 and Scope 2 but has not reported any Scope 3 emissions. Comparatively, in 2022, DMK Pharmaceuticals' total emissions were about 73,130,480 kg CO2e, with Scope 1 emissions at approximately 7,214,540 kg CO2e and Scope 2 emissions at around 65,915,940 kg CO2e (market-based). This indicates an increase in total emissions from 2022 to 2023. The company has not set any specific reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). As such, DMK Pharmaceuticals Corporation currently lacks formal commitments to reduce its carbon footprint in the future. Overall, while DMK Pharmaceuticals has made strides in reporting its emissions, the absence of reduction targets highlights an area for potential improvement in its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 5,575,500 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 59,894,300 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DMK Pharmaceuticals Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
